Ottawa's national security review, shutdown order ‘procedurally unfair': Hikvision
Hikvision makes the arguments in a court filing challenging a June 27 directive from the federal government to close down its business in Canada.
The company says the review process was procedurally unfair and the conclusion it reached was unreasonable.
Hickvision argues that government directive was based on incorrect assumptions.
Hikvision says Industry Minister Mélanie Joly abruptly concluded the review, did not properly communicate deadlines and declined to consider additional information the company wanted to provide.
Monday Mornings
The latest local business news and a lookahead to the coming week.
Joly said in an online post following the shutdown order that the government looked at information and evidence provided by Canada's security and intelligence community.
This report by The Canadian Press was first published July 9, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Hisense Ranks in Top 10 of Kantar BrandZ Chinese Global Brand Builders 2025 for Ninth Consecutive Year
QINGDAO, China, July 9, 2025 /CNW/ -- Hisense, a global leader in consumer electronics and home appliances, has once again been named among the top 10 most global Chinese brands in the newly released Kantar BrandZ Chinese Global Brand Builders 2025, jointly published by Google and Kantar. Hisense ranks No. 8 overall, maintaining its position in the top 10 for the ninth consecutive year, and remains the highest-ranked TV brand on the list. The BrandZ ranking evaluates Chinese brands' global strength using a comprehensive methodology that considers financial performance, consumer perception, brand power, and international presence. Hisense's sustained global momentum reflects its long-term investment in localized R&D, manufacturing, and marketing operations across multiple international markets — currently comprising 31 R&D centers, 36 industrial parks and production bases, and 64 overseas offices worldwide. Hisense's sports marketing strategy continues to be a key driver of its global brand equity. During UEFA EURO 2024™, the brand launched a multi-faceted video campaign on YouTube that combined emotional storytelling with product integration. This campaign successfully engaged diverse audiences across sports, technology, and home entertainment sectors worldwide. These efforts led to Hisense being honored in the 2025 YouTube Works Awards China, highlighting the brand's ability to create impactful and culturally relevant content on an international scale. As the FIFA Club World Cup™ 2025 unfolds, Hisense is further elevating its presence on the global sports stage. From stadium perimeter boards emblazoned with "Hisense 100'' TV, Global No.1" to immersive viewing experiences powered by its advanced ULED X and TriChroma Laser display technologies, the brand showcases both technological innovation and a consistent, global marketing narrative. By combining cutting-edge product innovation with high-profile sports sponsorships, Hisense has established a robust model for global brand building. According to Ipsos, its overseas brand awareness has grown from 30% in 2018 to 56% in 2024, demonstrating a significant increase in recognition and consumer trust internationally. Hisense's placement in the Kantar BrandZ Chinese Global Brand Builders 2025 ranking further confirms its status as a dynamic global brand that continuously evolves through innovation, strategic marketing, and meaningful connections with consumers worldwide. About Hisense Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV volume shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023- Q12025). As the first official partner of the FIFA Club World Cup 2025™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.
Vancouver Sun
2 hours ago
- Vancouver Sun
Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports
WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. 'Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals,' said Canadian Generic Pharmaceutical Association president Jim Keon. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said. Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said. He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. 'We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves,' Keon said. But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Drugmakers have said that tariffs on pharmaceuticals could also cause shortages in the United States and increase costs for Americans who need medicine. 'I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains,' Keon said. Keon said there is support for the Trump administration launching separate studies looking for ways to reduce prices and make the U.S. a more attractive market for drug manufacturing. Certain measures like harmonizing regulatory standards with those of other countries would help reduce unnecessary costs, he said. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
Edmonton Journal
2 hours ago
- Edmonton Journal
Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports
Drugmakers say that tariffs on pharmaceuticals could cause shortages in the U.S. and increase costs for Americans who need medicine. Photo by WilliamWASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by David Staples, Keith Gerein and others, Oilers news from Cult of Hockey, Ask EJ Anything features, the Noon News Roundup and Under the Dome newsletters. Unlimited online access to Edmonton Journal and 15 news sites with one account. Edmonton Journal ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by David Staples, Keith Gerein and others, Oilers news from Cult of Hockey, Ask EJ Anything features, the Noon News Roundup and Under the Dome newsletters. Unlimited online access to Edmonton Journal and 15 news sites with one account. Edmonton Journal ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors 'Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals,' said Canadian Generic Pharmaceutical Association president Jim Keon. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Get the latest headlines, breaking news and columns. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said. Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said. He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. 'We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves,' Keon said. But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market.
